X
(All Fields are required)
Issue Brief

Antibiotic Innovation: The Threat and the Pipeline


The Superbug Threat explores the emergence of antibiotic-resistant bacteria and its impact on human health, as well as the shrinking pipeline of new antibiotics.

Related Resources

FDA Releases Draft Guidance on Antibacterial Drug Development

Other Resource

Nearly a year after the enactment of the Generating Antibiotic Incentives Now Act, the U.S. Food and Drug Administration has released draft guidance for industry on developing antibacterial therapies for patients with unmet medical needs.

More

Bipartisan Senate Bill Introduced to Combat Superbugs

Senator Dianne Feinstein (D-CA) today introduced the Preventing Antibiotic Resistance Act, a bipartisan bill that would eliminate certain antibiotic-related practices that contribute to the rise of drug-resistant bacteria and endanger human health. The legislation is co-sponsored by Senators Susan Collins (R-ME), Kirsten Gillibrand (D-NY), Jack Reed (D-RI), Barbara Boxer (D-CA) and Maria Cantwell (D-WA).

More

Drug Development for Limited Populations: A New Proposed Pathway

Issue Brief
The lack of new antibiotics and the rise in drug resistance have rendered some serious and life-threatening infections untreatable, and the health care community is searching for ways to bring innovative new drugs to patients whose treatment options are limited or nonexistent. More

Bibliography on Antibiotic Resistance and Food Animal Production

This bibliography lists the latest published scientific and economic literature concerning the contribution of routine antibiotic use in food animals to the growing public health crisis of human antibiotic resistance.  Research on how antibiotic use in food animal production contributes to the growing health crisis of antibiotic resistance dates back more than 30 years. 

More

A New Pathway for Antibiotic Innovation: Exploring Drug Development for Limited Populations

Other Resource

As multidrug-resistant infections have grown more prevalent, few new antibiotics are reaching the market. This is attributed, in part, to the economic and regulatory challenges associated with their development. Recently, stakeholders have endorsed a novel regulatory pathway to approve these lifesaving drugs for use in limited patient populations — namely those at highest risk and with few or no other options.

More